<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00293124</url>
  </required_header>
  <id_info>
    <org_study_id>CECOG/GIST 1.2.001</org_study_id>
    <secondary_id>CSTI571BIC07</secondary_id>
    <nct_id>NCT00293124</nct_id>
  </id_info>
  <brief_title>Open-label Trial of GlivecWith Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors</brief_title>
  <official_title>An Open-label Trial of Glivec in Patients With Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors Expressing C-kit.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central European Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central European Cooperative Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The rationale is to assess the clinical and biological activity of Imatinib and to compare&#xD;
      the data with historic data.&#xD;
&#xD;
      Additionally this study has been designed to gain more experience with the treatment of GIST&#xD;
      in several Central and Eastern European Countries.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter open label clinical trial to be performed in patients with incurable&#xD;
      malignant GISTs that are unresectable or metastatic. Approximately 150 patients will enter&#xD;
      the trial.&#xD;
&#xD;
      Patients will receive Imatinib 400 mg p.o./day for a period of up to 24 months provided that&#xD;
      in the opinion of the investigator the patient is benefiting from treatment with Imatinib,&#xD;
      and in the absence of any safety concerns.&#xD;
&#xD;
      Treatment after completion of the 24 months study is at the discretion of the investigator.&#xD;
      Imatinib should be increased to 600 mg p.o./day and then to 400 mg b.i.d if the patient is&#xD;
      progressing on the respective dose level.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Disease Progression</measure>
    <time_frame>until PD</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Disease Progression</measure>
    <time_frame>until PD</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>until death</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">125</enrollment>
  <condition>Gastrointestinal Stromal Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glivec</intervention_name>
    <description>400mg p.o./day in a population of patients with locally advanced (=not amenable to surgery with curative intent) or metastatic malignant GIST. Glivec® may be increased to 600 mg p.o./day and then 800 mg p.o./day (400 mg b.i.d.) if the patient is progressing</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients &gt;= 18 years of age&#xD;
&#xD;
          -  Histologically documented diagnosis of GIST which is malignant as well as unresectable&#xD;
             (=not amenable to surgery with curative intent) and/or metastatic and therefore&#xD;
             incurable Immunohistochemical documentation of c-kit (CD117) expression by tumor&#xD;
&#xD;
          -  At least one measurable site of disease (as defined by Southwestern Oncology Group&#xD;
             Solid Tumor Response Criteria) which has not been previously embolised or irradiated&#xD;
&#xD;
          -  Performance status 0,1, 2 or 3 (ECOG)&#xD;
&#xD;
          -  Adequate end organ function, defined as the following: total bilirubin &lt; 1.5 x ULN,&#xD;
             SGOT and SGPT &lt; 2.5 x UNL (or &lt; 5 x ULN if hepatic metastases are present), creatinine&#xD;
             &lt; 1.5 x ULN, ANC &gt; 1.5 x 109/L, platelets &gt; 100 x 109/L&#xD;
&#xD;
          -  Female patients of child-bearing potential must have negative pregnancy test within 7&#xD;
             days before initiation of study drug dosing. Post menopausal women must be amenorrheic&#xD;
             for at least 12 months to be considered of non-childbearing potential. Male and female&#xD;
             patients of reproductive potential must agree to employ an effective barrier method of&#xD;
             birth control throughout the study and for up to 3 months following discontinuation of&#xD;
             study drug&#xD;
&#xD;
          -  Life expectancy of at least 6 months&#xD;
&#xD;
          -  Written, voluntary, informed consent&#xD;
&#xD;
          -  Patients who were previously treated with chemotherapy will be eligible for this study&#xD;
&#xD;
          -  Patient who are at least 5 years free of melanoma will be eligible for this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has received any other investigational agents within 28 days of first day of&#xD;
             study drug dosing&#xD;
&#xD;
          -  Patient is &lt; 5 years free of another primary malignancy except: if the other primary&#xD;
             malignancy is not currently clinically significant nor requiring active intervention&#xD;
             and CECOGs' approval is obtained, or if other primary malignancy is a basal cell skin&#xD;
             cancer or a cervical carcinoma in situ. Existence of any other malignant disease is&#xD;
             not allowed&#xD;
&#xD;
          -  Patient with Grade III/IV cardiac problems as defined by the New York Heart&#xD;
             Association Criteria. (i.e., congestive heart failure, myocardial infarction within 6&#xD;
             months of study)&#xD;
&#xD;
          -  Female patients who are pregnant or breast-feeding.&#xD;
&#xD;
          -  Patient has a severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes,&#xD;
             chronic renal disease, or active uncontrolled infection)&#xD;
&#xD;
          -  Patient has a known brain metastasis&#xD;
&#xD;
          -  Patient has an acute or known chronic liver disease (i.e., chronic active hepatitis,&#xD;
             cirrhosis)&#xD;
&#xD;
          -  Patient has a known diagnosis of human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Patient received chemotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin-C)&#xD;
             prior to study entry&#xD;
&#xD;
          -  Patient previously received radiotherapy to &gt;= 25 % of the bone marrow&#xD;
&#xD;
          -  Patient had a major surgery within 2 weeks prior to study entry&#xD;
&#xD;
          -  Patient with any significant history of non-compliance to medical regimens or with&#xD;
             inability to grant reliable informed consent&#xD;
&#xD;
          -  Therapeutic anticoagulation with warfarin (e.g. Coumadin® or Coumadine®)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Brodowicz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Clinic of Internal Medicine I / Clinical Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AKH, Universitätsklinik für Innere Medizin 1</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology Sarajevo</name>
      <address>
        <city>Sarajevo</city>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBALO National Oncology Center</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Oncological Center Hospital</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sofia Cancer Center compl. Mladost ,</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Split, Center of Oncology</name>
      <address>
        <city>Split</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Rebro</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FN Bulovka</name>
      <address>
        <city>Prague</city>
        <zip>186 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radioterapeticko-onkologicke. Oddeleni FN Motol</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lithuanian Oncology Center,</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul Oncologic Bucuresti</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul Oncologic Cluj</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emergency Clinical County Hospital , Clin Oncol. Dep</name>
      <address>
        <city>Craiova</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut za onkologiju i</name>
      <address>
        <city>Beograd</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Oncology</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Institute Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Bosnia and Herzegovina</country>
    <country>Bulgaria</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>Lithuania</country>
    <country>Romania</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Slovenia</country>
  </location_countries>
  <removed_countries>
    <country>Former Serbia and Montenegro</country>
  </removed_countries>
  <link>
    <url>http://www.cecog.org</url>
    <description>Related Info</description>
  </link>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>February 16, 2006</study_first_submitted>
  <study_first_submitted_qc>February 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2006</study_first_posted>
  <last_update_submitted>August 11, 2015</last_update_submitted>
  <last_update_submitted_qc>August 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastrointestinal Stromal Tumors</keyword>
  <keyword>Glivec</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

